



## Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020

December 7, 2020

***The Nasdaq Listing Council, on its own motion, will consider if the Company should have been granted a longer period within which to evidence compliance with the \$1.00 per share minimum bid price requirement***

**SAN FRANCISCO, CA / ACCESSWIRE / December 7, 2020 /** Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company received an unsolicited letter on December 2, 2020 from the Office of Appeals and Review of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Nasdaq Listing and Hearing Review Council (the "Listing Council") had exercised its discretion to call for review the October 28, 2020 decision of the Nasdaq Listing Qualifications Panel (the "Panel"). By its decision, the Panel granted the Company an extension to remedy the bid price deficiency, but only through December 23, 2020. Pursuant to the Nasdaq Listing Rules, the Panel had the discretion to grant Jaguar an extension through March 10, 2021.

The Listing Council stated that it will consider whether the Panel should have granted Jaguar a longer period to regain compliance with the bid price requirement and that, during the pendency of the Listing Council's review, the terms of the Panel's October 28, 2020 decision have been stayed.

"We were very happy to learn that the Listing Council has exercised its discretion to review the Panel's decision," Lisa Conte, Jaguar's president, and CEO said. "We believe our efforts since the second quarter of 2020 to implement our expanded patient access programs for Mytesi® (crofelemer) and our focus on long-term investors and non-dilutive financings, including our recent royalty-based capital infusion of \$6.0 million, are improving our long-term financial prospects. Additionally, with the initiation this past October by our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., of the pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy ("cancer therapy-related diarrhea" (CTD)), and our recently announced plans to develop and commercialize crofelemer for the possible indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea - initially to be studied in a 'long-hauler' COVID-19 recovery patient population in Europe - we believe the value generated in the Company will be realized as we work to regain compliance with the Nasdaq bid price requirement."

### **About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.**

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit <https://jaguar.health>. For more information about Napo, visit <http://www.napopharma.com>.

### **About Mytesi®**

Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy, and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at [Mytesi.com](http://Mytesi.com). Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal *Croton lechleri* tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

### **Forward-Looking Statements**

*Certain statements in this press release constitute "forward-looking statements." These include statements regarding the anticipated date of the Company's receipt of the Listing Counsel's decision, the belief that the Company's efforts since the second quarter of 2020 to implement the expanded patient access programs for Mytesi, and Jaguar's focus on long-term investors and non-dilutive financings, including the Company's recent royalty-based capital infusion of \$6.0 million, are improving Jaguar's long-term financial prospects, and the belief that with the initiation, this past*

October by Napo of the pivotal Phase 3 clinical trial of crofelemer (Mytesi) for CTD, and the Company's plans to develop and commercialize crofelemer for the possible indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea-initially to be studied in a 'long-hauler' COVID-19 recovery patient population in Europe-the value generated in the Company will be realized as Jaguar plans to regain compliance with the Nasdaq minimum bid price requirement. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.

**CONTACT:**

Peter Hodge  
Jaguar Health, Inc.  
[phodge@jaguar.health](mailto:phodge@jaguar.health)  
Jaguar-JAGX

**SOURCE:** Jaguar Health, Inc.

[accesswire.com](https://www.accesswire.com)

<https://www.accesswire.com/619590/Nasdaqs-Listing-and-Hearing-Review-Council-Stays-Panel-Determination-Requiring-Jaguar-Healths-Compliance-with-the-Bid-Price-Requirement-by-December-23-2020>